76
Participants
Start Date
March 29, 2021
Primary Completion Date
July 21, 2023
Study Completion Date
July 21, 2023
Berzosertib
Participants received Berzosertib at a dose of 105 milligrams per square meter (mg/m\^2 ) intravenously on Day 2 and Day 5 of each 21-day cycle until disease progression or other criteria for study intervention discontinuation are met.
Berzosertib
Participants received Berzosertib at a dose of 210 mg/m\^2 intravenously on Day 2 and Day 5 of each 21-day cycle in DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
Topotecan
Participants received Topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in DL1 and DL2 of safety run-in part and main part until disease progression or other criteria for study intervention discontinuation are met.
National Cancer Institute, Bethesda
Southeastern Medical Oncology Center, Goldsboro
FirstHealth of the Carolinas, Inc., Pinehurst
Toledo Clinic, Toledo
Summa Health, Akron
Cancer & Hematology Centers of Western Michigan, Grand Rapids
Azienda Ospedaliero Universitaria Pisana (Presidio di Cisanello), Pisa
MidAmerica Cancer Care, Kansas City
Cotton-O'Neil Clinical Research Center, Hematology and Oncology, Topeka
Millennium Physicians Association, LLP, Houston
Providence Medical Foundation, Santa Rosa
St Joseph Heritage Healthcare, Santa Rosa
NJ Center for Cancer Research, Brick
Centre Hospitalier de l'Ardenne, Arlon
Institut Jules Bordet - Department of Institut Jules Bordet, Brussels
Universitair Ziekenhuis Gent, Ghent
AZ Delta, Roeselare
CHU UCL Namur - Mont-Godinne, Yvoir
Beijing Cancer Hospital, Beijing
Jilin Cancer Hospital, Changchun
Sichuan Cancer Hospital, Chengdu
West China Hospital, Sichuan University, Chengdu
Jiangsu Province Hospital, Nanjing
Liaoning Cancer Hospital & Institute, Shenyang
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
The First Affiliated Hospital of Zhejiang University school of medicine, Zhejiang
Institut Bergonié, Bordeaux
Centre Hospitalier Intercommunal de Créteil - Service de Pneumologie, Créteil
Hopital Albert Calmette - CHU Lille - service de pneumologie et immuno allergologie, Lille
CHU Poitiers - Hôpital la Milétrie - service d'oncologie médicale, Poitiers
CHU Nantes - Hôpital Guillaume et René Laënnec - Service de Pneumologie, Saint-Herblain
CHU de Strasbourg - Nouvel Hôpital Civil - Service de Pneumologie, Strasbourg
"IRCCS Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori Dino Amadori - IRST", Meldola
Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda), Milan
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica, Rome
National Cancer Center Hospital, Chūōku
Kansai Medical University Hospital, Hirakata-shi
National Cancer Center Hospital East, Kashiwa-shi
Cancer Institute Hospital of JFCR, Kōtoku
Kindai University Hospital, Osaka
Kurume University Hospital, Osaka
Osaka Medical and Pharmaceutical University Hospital, Takatsuki-shi
Hospital Clinic de Barcelona, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Hospital Clinico Universitario Virgen de la Victoria - Oncology Service, Málaga
Hospital Universitario Virgen de la Victoria, Málaga
Hospital Universitario Virgen Macarena, Seville
Istituto Nazionale Tumori Regina Elena IRCCS, Roma
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY